Combination therapy of pegylated interferon alpha 2a and ruxolitinib in myelofibrosis: a case report

被引：0
|
作者：
Hindilerden, F. [1 ]
Demiriz, I. [1 ]
机构：
[1] SBU Bakirkoy Dr Sadi Konuk Egitim & Arastirma Has, Hematol Klin, Istanbul, Turkey
来源：
LEUKEMIA RESEARCH | 2019年 / 85卷
关键词：
D O I：
10.1016/S0145-2126(19)30319-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PP-24
引用
收藏
页码：S48 / S48
页数：1
相关论文
共 50 条
  • [21] Outcomes of response guided therapy with pegylated interferon alpha 2a in chronic hepatitis B and D
    Gherlan, George Sebastian
    Lazar, Stefan
    Culinescu, Augustina
    Daniela, Smadu
    Cazan, Andreea Ruxandra
    Popescu, Corneliu Petre
    Paunescu, Adelina
    Filip, Laurentiu
    Florescu, Simin
    Calistru, Petre
    Ceausu, Emanoil
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E465 - E465
  • [22] A Case of Severe Thrombocytopenia in a Patient with Chronic Hepatitis C Caused by a Single Administration of Pegylated Interferon Alpha 2a Subsequent to 48 Weeks of Pegylated Interferon Alpha 2b Plus Ribavirin Therapy
    Kato, Hideaki
    Fujishiro, Takuya
    Narita, Makoto
    INTERNAL MEDICINE, 2010, 49 (16) : 1741 - 1744
  • [23] Induction of a sarcoidosis under therapy with pegylated interferon-α2a
    Meller, S
    Reifenberger, J
    Ruzicka, T
    Homey, B
    HAUTARZT, 2006, 57 (04): : 317 - 318
  • [24] Pegylated interferon alpha 2b and pegylated interferon alpha 2a exhibit different anti-proliferative activity in vitro.
    Leaman, D
    Brassard, D
    Cox, S
    Spond, J
    Gavor, S
    DeLorenzo, M
    Youngster, S
    Bausch, J
    Bordens, R
    Grace, MJ
    HEPATOLOGY, 2002, 36 (04) : 547A - 547A
  • [25] Pegylated interferon alpha 2a for the treatment of hepatitis C virus infection
    Maughan, Ashly
    Ogbuagu, Onyema
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (02) : 219 - 227
  • [26] Pegylated Interferon Alpha 2a for the Treatment of Ocular Surface Squamous Neoplasia
    Park, Jongyeop
    Han, Jisang
    Chung, Tae-Young
    Lim, Dong Hui
    Choi, Chul Young
    CORNEA, 2022, 41 (10) : 1271 - 1275
  • [27] Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis
    Gowin, K.
    Kosiorek, H.
    Dueck, A.
    Mascarenhas, J.
    Hoffman, R.
    Reeder, C.
    Camoriano, J.
    Tibes, R.
    Gano, K.
    Palmer, J.
    Mesa, R.
    LEUKEMIA RESEARCH, 2017, 60 : 31 - 35
  • [28] Results of Response-Guided Therapy with Pegylated Interferon Alpha 2a in Chronic Hepatitis B and D
    Gherlan, George S.
    Lazar, Stefan D.
    Culinescu, Augustina
    Smadu, Dana
    Vatafu, Andreea R.
    Popescu, Corneliu P.
    Florescu, Simin A.
    Ceausu, Emanoil
    Calistru, Petre I.
    TROPICAL MEDICINE AND INFECTIOUS DISEASE, 2024, 9 (04)
  • [29] Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy
    Derbala, M. F.
    El Dweik, N. Z.
    Al Kaabi, S. R.
    Al-Marri, A. D.
    Pasic, F.
    Bener, A. B.
    Shebl, F. M.
    Amer, A. M.
    Butt, M. T.
    Yakoob, R.
    John, A.
    Al Mohanadi, M.
    Al Khinji, M. A.
    JOURNAL OF VIRAL HEPATITIS, 2008, 15 (08) : 591 - 599
  • [30] Acute pericarditis due to pegylated interferon alpha therapy for chronic HCV hepatitis - Case report
    Cristina Popescu
    Victoria Arama
    Smaranda Gliga
    BMC Gastroenterology, 11
12345